|
29 Jun 2025 |
SIS
|
Consensus Share Price Target
|
375.10 |
412.25 |
- |
9.90 |
buy
|
|
|
|
|
05 May 2025
|
SIS
|
Keynote Capitals Ltd
|
375.10
|
361.00
|
325.35
(15.29%)
|
Target met |
Buy
|
|
|
Quarterly Update Q4FY25
|
|
01 May 2025
|
SIS
|
Motilal Oswal
|
375.10
|
400.00
|
337.50
(11.14%)
|
6.64 |
Buy
|
|
|
SIS (SECIS)’s 4QFY25 revenue was up 9.3% YoY/1.9% QoQ at INR34.27b, largely in line with our estimate of INR34.6b. Revenue growth was aided by 12.9% YoY growth in Facility management, whereas India Security/International security posted 9.6%/7.7% growth YoY.
|
|
30 Jan 2025
|
SIS
|
Keynote Capitals Ltd
|
375.10
|
414.00
|
330.80
(13.39%)
|
10.37 |
Buy
|
|
|
Quarterly Update Q3FY25
|
|
31 Oct 2024
|
SIS
|
Keynote Capitals Ltd
|
375.10
|
483.00
|
402.00
(-6.69%)
|
28.77 |
Buy
|
|
|
Quarterly Update Q2FY25
|
|
30 Oct 2024
|
SIS
|
Axis Direct
|
375.10
|
540.00
|
400.85
(-6.42%)
|
43.96 |
Buy
|
|
|
Given the company's strong recovery potential backed by strong deal wins and improved client engagement, we maintain our BUY recommendation on the stock
|
|
29 Oct 2024
|
SIS
|
Motilal Oswal
|
375.10
|
480.00
|
386.05
(-2.84%)
|
27.97 |
Buy
|
|
|
SIS (SECIS)’s 2QFY25 revenue was up 6.3% YoY/4.4% QoQ at INR32.68b, largely in line with our estimate of INR34.51b.
|
|
29 Jul 2024
|
SIS
|
Keynote Capitals Ltd
|
375.10
|
585.00
|
421.25
(-10.96%)
|
55.96 |
Buy
|
|
|
Quarterly Update Q1FY25
|
|
26 Jul 2024
|
SIS
|
Axis Direct
|
375.10
|
540.00
|
419.75
(-10.64%)
|
43.96 |
Buy
|
|
|
We maintain our BUY recommendation on the stock.
|
|
06 May 2024
|
SIS
|
Keynote Capitals Ltd
|
375.10
|
441.00
|
440.50
(-14.85%)
|
Target met |
Buy
|
|
|
Quarterly Update Q4FY24
|
|
03 May 2024
|
SIS
|
Axis Direct
|
375.10
|
540.00
|
455.15
(-17.59%)
|
|
Buy
|
|
|
Recommendation: Given the company's strong recovery potential backed by strong deal wins and improved client engagement, we maintain our BUY recommendation on the stock.
|
|
01 Feb 2024
|
SIS
|
Axis Direct
|
375.10
|
540.00
|
488.50
(-23.21%)
|
|
Buy
|
|
|
Given the company's strong recovery potential backed by strong deal wins and improved client engagement, we maintain our BUY recommendation on the stock.
|
|
01 Feb 2024
|
SIS
|
Keynote Capitals Ltd
|
375.10
|
741.00
|
488.50
(-23.21%)
|
|
Buy
|
|
|
Quarterly Update Q3FY24
|
|
01 Nov 2023
|
SIS
|
Keynote Capitals Ltd
|
375.10
|
794.00
|
429.40
(-12.65%)
|
|
Buy
|
|
|
Quarterly Update Q2FY24
|
|
01 Nov 2023
|
SIS
|
Axis Direct
|
375.10
|
475.00
|
429.40
(-12.65%)
|
Target met |
Buy
|
|
|
Given the company's strong recovery potential backed by strong deal wins and improved client engagement, we maintain our BUY recommendation on the stock.
|
|
21 Sep 2023
|
SIS
|
Keynote Capitals Ltd
|
375.10
|
837.00
|
426.10
(-11.97%)
|
|
Buy
|
|
|
Initiating Coverage Report
|
|
28 Jul 2023
|
SIS
|
Axis Direct
|
375.10
|
475.00
|
434.65
(-13.70%)
|
Target met |
Buy
|
|
|
Recommendation: Given the company's strong recovery potential backed by strong deal wins and improved client engagement, we maintain our BUY recommendation on the stock.
|
|
05 May 2023
|
SIS
|
Axis Direct
|
375.10
|
425.00
|
383.35
(-2.15%)
|
Target met |
Buy
|
|
|
Given the company's strong recovery potential backed by strong deal wins and improved client engagement, we maintain our BUY recommendation on the stock.
|
|
06 Feb 2023
|
SIS
|
Axis Direct
|
375.10
|
425.00
|
345.95
(8.43%)
|
Target met |
Buy
|
|
|
Recommendation: Given the company's strong recovery potential backed by strong deal wins and improved client engagement, we maintain our BUY recommendation on the stock.
|
|
04 Nov 2022
|
SIS
|
Axis Direct
|
375.10
|
475.00
|
411.35
(-8.81%)
|
Target met |
Buy
|
|
|
We recommend a BUY rating on the stock and assign an 18x P/E multiple to its FY24E earnings of Rs 28.4/share which gives a TP of Rs 475/share, implying an upside of 15% from the CMP.
|
|
06 May 2022
|
SIS
|
Axis Direct
|
375.10
|
590.00
|
486.40
(-22.88%)
|
|
Buy
|
|
|
We recommend a BUY rating on the stock and assign a 21x P/E multiple to its FY24E earnings of Rs 28.4/share which gives a TP of Rs 590/share, implying an upside of 13% from the CMP.
|